Retatrutide Phase 3 TRIUMPH-2 and TRIUMPH-3 positive; up to 22.6% weight loss

Lilly reported positive topline results from two Phase 3 trials of retatrutide, its triple GIP, GLP-1 and glucagon agonist. In TRIUMPH-2, adults with obesity and type 2 diabetes lost up to 20.8% of body weight at 80 weeks, and in TRIUMPH-3 adults with severe obesity and established cardiovascular disease lost up to 22.6%. Lilly plans to file a Biologics License Application with the FDA in the first quarter of 2027.

• TRIUMPH-2: up to 20.8% weight loss at 80 weeks (12 mg)
• TRIUMPH-3: up to 22.6% weight loss in adults with severe obesity and established CVD
• Discontinuation due to adverse events of 7.7% (TRIUMPH-2) and 13.5% (TRIUMPH-3) at 12 mg
• BLA submission to the FDA planned for Q1 2027